Cyrus Ardalan becomes new Chair of IFFIm Board
- Press Releases
- Cyrus Ardalan becomes new Chair of IFFIm Board
Cyrus Ardalan becomes new Chair of IFFIm Board
9 January 2018
Ardalan succeeds René Karsenti, who oversaw nearly US$ 2.5 billion in bond issuances, entry into Sukuk markets.
Cyrus Ardalan (right), new IFFIm Board Chair, with outgoing Board Chair René Karsenti.
London, 9 January 2018 – The Board of Directors of The International Finance Facility for Immunisation (IFFIm) has selected Cyrus Ardalan, a London-based international investment banking leader, as its new Chair. Mr Ardalan, who began his term as IFFIm Chair on January 1, succeeds René Karsenti, who has served as Chair since 2012.
“I am delighted to have the opportunity to succeed René and to chair the IFFIm board,” said Mr Ardalan. “During his tenure René made an exceptional contribution in leading IFFIm, with its innovative financial structure, to support Gavi, the Vaccine Alliance’s efforts to save the lives of millions of children in some of the poorest countries globally. I look forward to chairing a board that brings together extensive backgrounds in supranational and development finance and continues to build on IFFIm’s work as one of best examples of socially responsible investing.”
“As a member of IFFIm’s Board since 2013, Cyrus has already contributed enormously to IFFIm’s evolution as an exemplary socially responsible investment tool,” said Mr Karsenti. “And with a long career in international investment banking, he offers the right combination of experience, prudence, intellect and compassion that a complex and cutting-edge institution like IFFIm needs to succeed.”
Cyrus Ardalan is the Non-Executive Director and Chairman of Citigroup Global Markets Ltd. He is also Chairman of OakNorth Bank, as well as Chairman of the Financial Services Advisory Board of Alvarez and Marsal."
"I look forward to chairing a board that brings together extensive backgrounds in supranational and development finance and continues to build on IFFIm’s work as one of best examples of socially responsible investing. "
Cyrus Ardalan, Chair of the IFFIm Board
Previously, he was Vice Chairman of Barclays and head of Public Policy and Government Relations, as well as Vice Chairman of Barclays Capital, where he had a variety of senior roles. Ardalan joined Barclays Capital in 2000 from BNP Paribas, where he held a number of senior positions between 1990 and 2000 in London and New York, including Global Head of Bonds, Global Head of Fixed Income Marketing and Head of BNP Paribas Capital Markets’ activities in North and South America. Previously, Mr. Ardalan was a Managing Director at Chemical Bank and Division Chief of Treasury Operations at the World Bank in Washington.
Mr. Ardalan has previously served as Chairman of the Board of the International Capital Markets Association (ICMA) and as a member of the board of the Dubai International Financial Centre (Dubai's offshore banking facility). A UK national, he is a graduate of University College London and Balliol College University of Oxford.
During his tenure as IFFIm’s Chair Mr. Karsenti, currently President of the International Capital Market Association (ICMA), oversaw seven IFFIm bond issuances which raised a total of US$ 2.5 billion, including two pioneering and award-winning forays into Islamic Sukuk markets.
“Gavi is immensely grateful to René Karsenti for his hard work and sound leadership as Chair of IFFIm, and we’re looking forward to tapping the tremendous store of energy, knowledge and wisdom that Cyrus brings to the role,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance.
“They and many other Board members have made IFFIm a role model for the entire field of global development, which faces constant funding challenges and unpredictability.”
"Gavi is immensely grateful to René Karsenti for his hard work and sound leadership as Chair of IFFIm, and we’re looking forward to tapping the tremendous store of energy, knowledge and wisdom that Cyrus brings to the role."
Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance
Since 2006, IFFIm has raised more than US$ 6 billion on bond markets to give Gavi the flexibility to meet immediate needs. To date, Gavi funding in the poorest countries around the world has resulted in the immunisation of close to 640 million children and averted more than 9 million deaths. For example, US$ 90.9 million of funds generated through IFFIm “Vaccine Bonds” went for emergency stockpiles contributing to the inoculation of more than 189 million people against yellow fever, and US$ 139 million of IFFIm funding supported targeted mass measles campaigns that reached an additional 328 million children.
Widely admired in the development finance community, IFFIm was singled out at the Third International Conference on Financing for Development, in 2015 in Addis Ababa, Ethiopia, which urged that it “be replicated to address broader development needs.”
In addition to overseeing Vaccine Bond issuances, Mr Ardalan and the Board will also evaluate the opportunity to extend IFFIm’s future roles to include more directly supporting Gavi’s market shaping activities, Gavi’s Cold Chain Equipment Optimisation Platform and rapid financing in response to disease outbreaks if Gavi decides to play an active role in this space.
The securities referred to in this document have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under the securities legislation of any state of the United States, and may not be offered or sold in the United States, other than pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. IFFIm does not presently intend to make a public offer of securities in the United States or to register any securities under the Securities Act. Any offering of securities will made by means of a prospectus that may be obtained from IFFIm and will contain detailed information about IFFIm and management as well as financial statements. The securities referred to in this document will only be offered or sold outside the United States in offshore transactions in reliance on Regulation S under the Securities Act.
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.